Globally, depression is a leading cause of disability and has remained so for decades.
Antidepressant medications have suboptimal outcomes and are too frequently associated …

Major depressive disorder (MDD) is a debilitating neuropsychological disorder, which has
caused serious health and socio-economic burdens worldwide. A growing body of evidence …

Background: Ayahuasca is a traditional Amazon brew and its potential antidepressant
properties have recently been explored in scientific settings. We conducted a double-blind …

Rationale Depression has the topmost prevalence of all psychiatric diseases. It is
characterized by a high recurrence rate, disability, and numerous and mostly unclear …

Regulation of emotions is generally associated exclusively with the brain. However, there is
evidence that peripheral systems are also involved in mood, stress vulnerability vs …

Ethnopharmacological relevance Xiaoyaosan (XYS), a classic description, has a history of
thousands of years for treating depression through invigorating the liver and strengthening …

Increasing evidence has demonstrated that inflammatory cytokines play an important role in
major depressive disorder (MDD) and are associated with treatment outcomes. Few studies …

Depression and obesity are both common disorders currently affecting public health,
frequently occurring simultaneously within individuals, and the relationship between these …

Brain-derived neurotrophic factor (BDNF) has been studied as a biomarker of major
depressive disorder (MDD). Besides diagnostic biomarkers, clinically useful biomarkers can …

Immune-inflammatory mechanisms are promising targets for antidepressant pharmacology.
Immune cell abnormalities have been reported in mood disorders showing a partial T cell …